Sublocade Patent Expiration

SUBLOCADE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9782402 INDIVIOR Injectable composition comprising buprenorphine
Jun, 2031

(6 years from now)

US9272044 INDIVIOR Injectable flowable composition buprenorphine
Jun, 2031

(6 years from now)

US9827241 INDIVIOR Injectable flowable composition comprising buprenorphine
Jun, 2031

(6 years from now)

US9498432 INDIVIOR Injectable flowable composition comprising buprenorphine
Jun, 2031

(6 years from now)

US10198218 INDIVIOR Injectable flowable composition comprising buprenorphine
Jun, 2031

(6 years from now)

US10592168 INDIVIOR Injectable flowable composition comprising buprenorphine
Jun, 2031

(6 years from now)

US10558394 INDIVIOR Injectable flowable composition comprising buprenorphine
Jun, 2031

(6 years from now)

US8975270 INDIVIOR Injectable flowable composition comprising buprenorphine
Sep, 2031

(7 years from now)

US8921387 INDIVIOR Injectable flowable composition comprising buprenorphine
Jan, 2032

(7 years from now)

US11839611 INDIVIOR Buprenorphine dosing regimens
Nov, 2035

(11 years from now)

US11000520 INDIVIOR Buprenorphine dosing regimens
Nov, 2035

(11 years from now)

US10646484 INDIVIOR Methods to treat opioid use disorder
Jun, 2038

(13 years from now)



Sublocade is a drug owned by Indivior Inc. It is used for opioid addiction and dependence, including treatment of opioid use disorder. Sublocade uses Buprenorphine as an active ingredient. Sublocade was launched by Indivior in 2017. It is is available in solution, extended release form for subcutaneous use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jun 22, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 30, 2020

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using BUPRENORPHINE ingredient

Market Authorisation Date: 30 November, 2017

Treatment: Treating addiction by subcutaneous injection of buprenorphine; Treating opioid addiction by subcutaneous injection of buprenorphine; Treating opioid dependency by administering buprenorphine once per ...

Dosage: SOLUTION, EXTENDED RELEASE

More Information on Dosage

SUBLOCADE family patents

Family Patents